[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360065-105":59,"doc-detail-360065-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-lasso-based-model-combining-mirna-and-clinical-variables-predicts-future-risk-of-breast-and-ovarian-cancer","A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer","","A lasso-based model integrates serum microRNA (miRNA) profiles with clinical variables to identify women at elevated risk of ovarian cancer within an institutional biobank of 1831 individuals. miRNA and metadata are mapped using lasso, followed by a linear classifier estimating a “BRCAness” phenotype and long-term risk. Tenfold cross-validation yields BRCA prediction AUC 0.98 (95% CI 0.94–1.0) and generalizes across age, cancer history, and race/ethnicity. In a separate cohort of 1044 trial subjects, the model correlates strongly with log 5-year relative risk (R=0.93).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-lasso-based-model-combining-mirna-and-clinical-variables-predicts-future-risk-of-breast-and-ovarian-cancer/360065/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-lasso-based-model-combining-mirna-and-clinical-variables-predicts-future-risk-of-breast-and-ovarian-cancer/360065.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data does the lasso-based model combine to predict risk?","Question",{"text":112,"@type":113},"It integrates serum miRNA profiles with clinical variables collected as metadata from electronic health records.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is risk prediction performed in the proposed approach?",{"text":117,"@type":113},"The miRNA and metadata are mapped into a two-dimensional space using lasso, and a linear classification model is trained to estimate a “BRCAness” phenotype and long-term cancer risk.",{"name":119,"@type":110,"acceptedAnswer":120},"How well does the model perform on predicting ovarian cancer risk?",{"text":121,"@type":113},"Across subgroups it achieves BRCA prediction AUC 0.98 (95% CI 0.94–1.0). In an independent cohort it strongly correlates with log 5-year relative risk (R=0.93), and direct prediction of future onset yields AUC 0.75 (95% CI 0.70–0.78).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360065,1790334090,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer  \nJames W. Webber1, Laura Wollborn2, Sudhanshu Mishra2, Stephanie Alimena2,3,4, Bryanna Testino2, Konrad Stawiski5, Wojciech Fendler5,6, Dipanjan Chowdhury3,6 & Kevin M. Elias1,4,7􀀍  \nHereditary breast and ovarian cancer syndrome (HBOC) is principally caused by germline mutations in BRCA1 and BRCA2 . However, most women with HBOC are undiagnosed, and some patients meeting clinical criteria for HBOC will have no identifiable mutation after genetic testing. Here, we deploy alasso-based model to combine serum miRNA profiles with clinical data to identify women at elevated risk for ovarian cancer among a population of 1831 individuals enrolled in an institutional biobank. The miRNA and metadata variables are mapped to two-dimensional space using lasso, after which a linear classification model is trained to estimate “BRCAness” and long-term risk of cancer. After tenfold crossvalidation, the method offers a BRCA prediction AUC score of 0.98 (95% CI 0.94–1.0) and generalizes across subgroups stratified by age, cancer history, and racial/ethnic group. To demonstrate the clinical relevance of this phenotype, we use the lasso-based model to assess 5-year ovarian cancer risk among an independent cohort of 1044 subjects agnostic to genetic testing results enrolled in a randomized clinical trial. In this unselected population, the output of the lasso-based model strongly correlates to the log 5-year relative risk of ovarian cancer (R = 0.93, 95% CI 0.83–0.97, p \u003C 0.0001). When the model was used to predict future onset of ovarian cancer directly, theAUC offered was AUC = 0.75 (95% CI  \n0.70–0.78). Together, these data suggest the proposed model is a predictor of future ovarian cancer risk.  \nKeywords Ovarian cancer, miRNA, BRCA1, BRCA2, Risk prediction, Lasso  \nHereditary breast and ovarian cancer syndrome (HBOC) is characterized by markedly increased lifetime risks of breast and ovarian cancer as well as melanoma, prostate, and pancreatic cancers1,2. The most commonly mutated genes in HBOC are the DNA homologous recombination (HR) genes BRCA1 and BRCA2, although mutations in a number of other moderate penetrance genes involved in HR can present a similar phenotype3. Moreover, many patients meeting clinical criteria for a diagnosis of HBOC have no identifiable mutation. Currently, the only clinical indications for genetic testing for HBOC are a personal history of a HBOC-related cancer, a strong family history of cancer which might suggest HBOC, or a close family relation with a known genetic mutation linked to HBOC4. Routine testing for HBOC is not recommended5. As a result, only 10% of the estimated 1 million BRCA1 or BRCA2 mutation carriers in the United States are aware of their mutation status and likely even lower percentages among the moderate penetrance genes6,7. Compounding this lack of awareness, conventional BRCA1 and BRCA2 testing panels have historically had poor representation of genetic variants seen in non-white European populations, leading to higher rates of variants of unknown significance (VUS) among non-white European racial and ethnic groups8. Moreover, these testing panels provide uncertain information about cancer risk for individuals with no identifiable mutation.  \n1Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. 2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA. 4Dana-Farber Cancer Institute, Boston, MA, USA. 5Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland. 6Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.  \n7Gynecologic Oncology Section, Obstet","cbCaikQHaZRvoydP","https://ap.wps.com/l/cbCaikQHaZRvoydP","pdf",3075175,12,"English","# Introduction\n## Hereditary breast and ovarian cancer syndrome (HBOC)\n## Need for improved risk assessment\n# Methods\n## Data sources and study populations\n## Lasso mapping and linear classification\n# Results\n## Cross-validation performance\n## Correlation with 5-year relative risk\n## Prediction of future ovarian cancer onset\n# Clinical relevance","[{\"question\":\"What data does the lasso-based model combine to predict risk?\",\"answer\":\"It integrates serum miRNA profiles with clinical variables collected as metadata from electronic health records.\"},{\"question\":\"How is risk prediction performed in the proposed approach?\",\"answer\":\"The miRNA and metadata are mapped into a two-dimensional space using lasso, and a linear classification model is trained to estimate a “BRCAness” phenotype and long-term cancer risk.\"},{\"question\":\"How well does the model perform on predicting ovarian cancer risk?\",\"answer\":\"Across subgroups it achieves BRCA prediction AUC 0.98 (95% CI 0.94–1.0). In an independent cohort it strongly correlates with log 5-year relative risk (R=0.93), and direct prediction of future onset yields AUC 0.75 (95% CI 0.70–0.78).\"}]","A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer | PDF",1790138664,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/359a30044e993342aed1ce1291d28588.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3552f6ecc2c872ccb6dd2a09584bda7a.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9af8e05156bac4fa11d03beaa6b73058.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f147d51f50cc7ea36bb76605cf8dcb2.webp",980,1287]